



2024/92

18.1.2024

DECISION OF THE EEA JOINT COMMITTEE No 106/2021
of 19 March 2021
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement
[2024/92]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

- (1) Commission Implementing Regulation (EU) 2020/1685 of 12 November 2020 amending Regulation (EU) No 37/2010 to classify the substance bupivacaine as regards its maximum residue limit ⁽¹⁾ is to be incorporated into the EEA Agreement.
- (2) Commission Implementing Regulation (EU) 2020/1712 of 16 November 2020 amending Regulation (EU) No 37/2010 to classify the substance lidocaine as regards its maximum residue limit ⁽²⁾ is to be incorporated into the EEA Agreement.
- (3) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following indents are added in point 13 (Commission Regulation (EU) No 37/2010) of Chapter XIII of Annex II to the EEA Agreement:

- ‘ **32020 R 1685**: Commission Implementing Regulation (EU) 2020/1685 of 12 November 2020 (OJ L 379, 13.11.2020, p. 44),
- **32020 R 1712**: Commission Implementing Regulation (EU) 2020/1712 of 16 November 2020 (OJ L 384, 17.11.2020, p. 3).’

Article 2

The texts of Implementing Regulations (EU) 2020/1685 and (EU) 2020/1712 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 20 March 2021, provided that all the notifications under Article 103(1) of the EEA Agreement have been made *.

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

⁽¹⁾ OJ L 379, 13.11.2020, p. 44.

⁽²⁾ OJ L 384, 17.11.2020, p. 3.

* No constitutional requirements indicated.

Done at Brussels, 19 March 2021.

For the EEA Joint Committee
The President
Clara GANSLANDT
